INDRAPRASTHA MEDICAL CORP

INDRAMEDCO · Pharma · NSE

₹377

Current Market Price

Below Fair Value

Fair Value (DCF)

₹676

Discount to FV

+79.6%

Valuation engine: DCF

Updated just now

DCF Sensitivity →

YieldIQ Score

40/100

Piotroski F-Score

7/9

Economic Moat

Wide

Confidence

59%

ROE

24.8%

Debt/Equity

0.05

WACC

9.7%

Market Cap

₹3,452 Cr

Quality & Valuation

Neutral model outputs — no recommendations.

ROCE

38.0%

Return on capital employed

EV / EBITDA

11.7×

Enterprise multiple

Debt / EBITDA

0.1×

Leverage vs earnings

Interest Coverage

72.4×

EBIT covers interest

Current Ratio

2.41×

Short-term liquidity

Asset Turnover

1.74×

Revenue per ₹ of assets

Revenue CAGR (3Y)

11.7%

3-year revenue growth

Revenue CAGR (5Y)

—

5-year revenue growth

DCF Scenario Analysis

vs CMP ₹376.55

Bear case

Discount -3.0%

Base case

Discount +44.3%

Bull case

Discount +54.2%

Ratio Trends

INDRAMEDCO · last 9 annual periods

ROE

24.8%

min 18.0%max 27.0%

ROCE

38.0%

min 24.9%max 42.4%

Operating Margin

—

min —max —

Debt / Equity

0.05×

min 0.01×max 0.07×

18.6×

min 9.1×max 18.6×

EV / EBITDA

11.7×

min 4.4×max 11.7×

Historical Financials

INDRAMEDCO · Annual, last 5 years· amounts in ₹Cr unless noted

Metric	2022 NSE_XBRL	2023 NSE_XBRL	2024 NSE_XBRL	2025 yfinance	2026 yfinance	CAGR
Revenue	₹862 Cr	₹1065 Cr	₹1204 Cr	₹1356 Cr	₹1483 Cr	+14.5%
EBITDA	₹115 Cr	₹157 Cr	₹207 Cr	₹267 Cr	₹296 Cr	+26.7%
EBIT	₹82.5 Cr	₹121 Cr	₹170 Cr	—	—	+19.8%
PAT	₹58.6 Cr	₹86.2 Cr	₹124 Cr	₹161 Cr	₹184 Cr	+33.0%
EPS (diluted)	₹6.39	₹9.40	₹13.52	—	—	+20.6%
CFO	₹94.3 Cr	₹144 Cr	₹200 Cr	₹157 Cr	₹167 Cr	+15.4%
CapEx	₹-29.5 Cr	₹-44.6 Cr	₹-69.4 Cr	₹-36.3 Cr	₹-59.6 Cr	—
FCF	₹64.8 Cr	₹99.9 Cr	₹131 Cr	₹120 Cr	₹108 Cr	+13.6%
Total Assets	₹462 Cr	₹555 Cr	₹723 Cr	₹852 Cr	₹991 Cr	+21.1%
Total Debt	₹5.3 Cr	₹2.5 Cr	₹34.0 Cr	₹32.8 Cr	₹36.9 Cr	+62.3%
Shareholders' Equity	₹325 Cr	₹379 Cr	₹478 Cr	₹597 Cr	₹740 Cr	+22.8%

CAGR computed across the visible window. Signs reverse if start value is zero or negative.

Peer Comparison

INDRAMEDCO vs 2 closest peers by market-cap band

Peer	MoS	Score	Verdict	ROE	PE
SHALBY SHALBY	—	—	Pending	0.6%	—
GPTHEALTH GPTHEALTH	—	—	Pending	15.7%	—

Click a ticker to view its fair-value analysis.

Dividend History

8 ex-dividend events on file. Source: NSE corporate-actions feed.

Total paid (5Y)

₹14.50/sh

Last payout

2025-09-18

₹4.50

Peak payout

₹4.50

Trailing yield

1.20%

Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).

AI Analysis Summary

Model-generated description of metrics. Not investment advice. INDRAPRASTHA MEDICAL CORP (INDRAMEDCO.NS) trades at 376.55 vs a model fair value of 676.45, a gap of 79.6%. Piotroski F-score: 7/9. Moat ...

Read full AI analysis →

Reverse DCF

Market-implied growth

What FCF growth is priced in →

Risk Analysis

Volatility & drawdown

Risk profile of INDRAMEDCO →

DuPont

ROE decomposition

Why ROE is what it is →

Technicals

RSI, MACD, MAs

Reference indicators →

News & Filings

Recent activity

BSE filings + news for INDRAMEDCO →

Compare

Head-to-head with peers

Compare INDRAMEDCO side by side →

Run Full Interactive Analysis

Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.

Analyse INDRAMEDCONow →

Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.